4 hours agoEurope Approves Sale of First Artificial Heart
Periskopi(5 years ago)
(5 years ago)The shares of the Carmat SA company have risen dramatically after the company received approval to sell artificial hearts to Europe, a 27-year-old effort by a French heart surgeon. Carmat shares have been raised for 66% this year, giving the company a total of 407m euros. Carms [...]
The shares of the Carmat SA company have risen dramatically after the company received approval to sell artificial hearts to Europe, a 27-year-old effort by a French heart surgeon.
Carmat shares have been raised for 66% this year, giving the company a total of 407m euros. Carmat this week secured CE certificate for the device, which means the company can now sell it to the European Union as a heart transplant bridge for heart patients.
The surgeon and inventor of the Alain Carpentier heart valve proposed developing an artificial heart in 1993. Carpentier established a laboratory and employed several engineers, and since then the project expanded over the years, news.net broadcasts.
Carma took 10 years to get the mark “CE” and this is a record for such a complex device as this. “We must now work with doctors and medical centres to provide our therapy for patients. The production phase will be delicate”, Carmat's chief executive said in an interview for BMF Business television.
Carmat plans to speed up the production of equipment in January, including an additional switch to companies for workers. Carmat's artificial heart has tremendous potential and could reach annual sales worth 700 million in Europe by 2030.
